Leukemia Research Reports最新文献

{"title":"A comprehensive case study on successful multimodal therapy in philadelphia chromosome-positive acute myeloid leukemia with NPM1 and IDH2 mutations","authors":"Syed Muhammad Waqar Haider ,&nbsp;Mehwish Zehra ,&nbsp;Nikesh N Shah ,&nbsp;Eduardo M Sotomayor ,&nbsp;David M Swoboda","doi":"10.1016/j.lrr.2024.100461","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100461","url":null,"abstract":"<div><p>A 67-year-old female came to Tampa General Hospital with Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) featuring an intriguing combination of mutations, including <em>NPM1</em> and <em>IDH2</em> mutations. Novel combination therapy with azacitidine, venetoclax and ponatinib allowed her to successfully achieve a complete response (CR) and undergo an allogeneic hematopoietic stem cell transplant (HSCT). This case report provides an overview of her clinical course, emphasizing the significance of integrated therapy and the challenges associated with balancing treatment for AML. It also underscores the importance of a multidisciplinary approach and careful monitoring of patients with complex hematologic conditions.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100461"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000517/pdfft?md5=2596c4784f9889a364c2caaf23574cb6&pid=1-s2.0-S2213048924000517-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140822895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CLINICAL IMPLICATIONS OF COPY NUMBER ALTERATION DETECTION USING PANEL-BASED NEXT-GENERATION SEQUENCING DATA IN MYELODYSPLASTIC SYNDROME","authors":"S.-H. Jung ,&nbsp;Y.-J. Chung","doi":"10.1016/j.lrr.2024.100426","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100426","url":null,"abstract":"<div><h3>Introduction</h3><p>Recurrent somatic mutations are found in about 90 % of the MDS patients, and some of the mutations are known to have a prognostic value at various clinical stages of myelodysplastic syndrome (MDS). However, there are no specific guidelines for the assessment of CNAs, and the CNA test is not included in standard practice in the diagnosis and prognostication of MDS. Thus, there is a need to evaluate whether the detection of CNAs, in addition to genetic mutations, has clinical significance. In this study.</p></div><div><h3>Methods</h3><p>Targeted deep sequencing of 28 well-known MDS-related genes was performed for 266 patients with MDS. DNA copy number was estimated using the targeted deep sequencing data.</p></div><div><h3>Results</h3><p>Overall, 215 (80.8 %) patients were found to have at least one somatic mutation; 67 (25.2 %) had at least one CNA; 227 (85.3 %) had either a somatic mutation or CNA; and 12 had CNA without somatic mutations. Considering the clinical variables and somatic mutations alone, multivariate analysis demonstrated that sex, revised International Prognostic Scoring System (IPSS-R), and NRAS and TP53 mutations were independent prognostic factors for overall survival. For AML-free survival, these factors were sex, IPSS-R, and mutations in NRAS, DNMT3A, and complex karyotype/TP53 mutations. When we consider clinical variables along with somatic mutations and CNAs, genetic alterations in TET2, LAMB4, U2AF1, and CBL showed additional significant impact on the survivals.</p></div><div><h3>Conclusions</h3><p>In conclusion, our study suggests that the concurrent detection of somatic mutations and targeted CNAs may provide clinically useful information for the prognosis of MDS patients.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100426"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000165/pdfft?md5=bb9a6504f28f2c39a136326e47d16d30&pid=1-s2.0-S2213048924000165-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROME- CORRELATION WITH CYTOMORPHOLOGY RESULTS","authors":"I. Mandac Smoljanovic ,&nbsp;T. Duic ,&nbsp;Z. Siftar ,&nbsp;S. Ostojic Kolonic","doi":"10.1016/j.lrr.2024.100416","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100416","url":null,"abstract":"<div><h3>Introduction</h3><p>In the absence of significant dysplasia in suspected myelodysplastic syndrome (MDS), flow cytometry (FC) analysis helps to distinguish clonal cytopenia. The aim of the study was to analyse the concordance of cytomorphological characteristics and flow cytometry in patients with newly diagnosed MDS in KB Merkur in the period from March 2016 to April 2023.</p></div><div><h3>Methods</h3><p>We analyzed bone marrow FC in 69 patients (38 men, 31 women) who were diagnosed with MDS based on bone marrow morphology.</p></div><div><h3>Results</h3><p>In 57 patients (82%), the morphological diagnosis of MDS was also confirmed in the flow cytometry findings. In 11 (91%) of a total of 12 patients in whom the FC analysis did not prove MDS, no blasts were observed in the cytological findings. The expression of CD34, CD117, CD13 and CD33 (cut off 20%) was analyzed in 57 patients in whom MDS was suspected in the myelogram and FC . CD117 and CD33 did not differ between groups, regardless of MDS subtype. CD34 and CD13 was statistically significantly higher in high-risk MDS than in low-risk MDS. There was no statistically significant difference in the level of hemoglobin and expression of CD antigen, while the level of platelets correlated negatively with the level of CD117, CD13 and CD34. The expression of CD34 positively correlated with the level of C reactive protein.</p></div><div><h3>Conclusions</h3><p>Flow cytometry in MDS is a valuable additional method in discriminating MDS from other forms of cytopenia to improve both diagnosis and prognosis, but there is a need to establish standard techniques in everyday use.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100416"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000062/pdfft?md5=2ae8fd39969090f896f7f77e7f4bf866&pid=1-s2.0-S2213048924000062-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DDX41 MUTATIONS DEFINE A DISTINCT SUBTYPE OF MYELOID NEOPLASMS.","authors":"H. Makishima","doi":"10.1016/j.lrr.2024.100437","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100437","url":null,"abstract":"<div><h3>Introduction</h3><p>Germline <em>DDX41</em> variants have been implicated in late-onset myeloid neoplasms (MNs). Despite an increasing number of publications, many important features of <em>DDX41</em>-mutated MNs remain unclear.</p></div><div><h3>Methods</h3><p>Here, we enrolled a total of 346 patients with <em>DDX41</em> pathogenic/likely pathogenic (P/LP) germline variants and/or somatic mutations from 9,082 MN patients, together with 525 first-degree relatives of <em>DDX41</em>-mutated and wild-type (WT) patients. We performed a comprehensive characterization of <em>DDX41</em>-mutated MNs.</p></div><div><h3>Results</h3><p>P/LP <em>DDX41</em> germline variants explained ∼80% of known germline predisposition to MNs in adults. These risk variants were 10-fold more enriched in Japanese MN cases (n=4,461) compared to a Japanese general population (n=20,238). This enrichment of <em>DDX41</em> risk alleles was much more prominent in male than female (20.7 vs. 5.0). P/LP <em>DDX41</em> variants conferred a large risk of developing MNs, which was negligible until 40 years old but rapidly increased to 49% by 90 years of age. <em>DDX41</em>-mutated MDS patients rapidly progressed to AML, which was, however, confined to those having truncating variants. Co-mutation patterns at diagnosis and at progression to AML were substantially different between <em>DDX41</em>-mutated and -WT cases, where none of the co-mutations affected clinical outcomes. Even <em>TP53</em> mutations made no exceptions and their dismal effect, including multi-hit allelic status, on survival was almost completely mitigated by the presence of <em>DDX41</em> mutations. Finally, outcomes were not affected by the conventional risk stratifications including the revised/molecular International Prognostic Scoring System (IPSS-R/M).</p></div><div><h3>Conclusions</h3><p>Our findings establish that <em>DDX41</em>-mutated MDS defines a unique subtype of MNs that is distinct from other MNs.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100437"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221304892400027X/pdfft?md5=9f353ff600f65b73db1fbb5b5da6ac63&pid=1-s2.0-S221304892400027X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PHASE 3B STUDY DESIGN: COMPARING TREATMENT PREFERENCE BETWEEN ORAL DECITABINE/CEDAZURIDINE AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME, LOW-BLAST ACUTE MYELOID LEUKAEMIA, OR CHRONIC MYELOMONOCYTIC LEUKAEMIA","authors":"A. Enjeti ,&nbsp;C. Fong ,&nbsp;T. Paine ,&nbsp;F. Castaldi ,&nbsp;G. Van Wyk ,&nbsp;R. Walton ,&nbsp;H. Keer","doi":"10.1016/j.lrr.2024.100440","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100440","url":null,"abstract":"<div><h3>Introduction</h3><p>There is uncertainty about how choice of therapy in myelodysplasia (MDS), low-blast count AML (LB-AML) or chronic myelomonocytic leukaemia (CMML) is made by patients, physicians and carers when &gt;1 treatment type is available. This study's primary objective is to compare patients’ treatment preference using the patient ‘treatment preference in myelodysplasia questionnaire’ (pTPMQ). Secondary objectives include evaluation of preference by carers (cTPMQ), and clinicians (mTPMQ).</p></div><div><h3>Methods</h3><p>This phase 3b, open-label, multi-centre study (NCT05883956), with sites in Australia and New Zealand, will compare preference between oral decitabine/cedazuridine (Treatment A) and SC AZA (Treatment B). The study design includes 28 days of screening, four continuous 28-day cycles of study treatment, and a follow-up period with two 28-day cycles of continued therapy. Patients (N=42) will be randomised to two balanced treatment sequences: ABBA or BAAB (Figure 1). Patients will express a preference twice in the study, first after completing Cycle 2, then after completing Cycle 4. This will be assessed via the pTPMQ. Clinician and carer preference will also be assessed.</p></div><div><h3>Results</h3><p>Trial to be activated in Australia and New Zealand, with first patient recruited in December 2023. We will report the primary and secondary objectives. Exploratory objectives including treatment discontinuation rates, quality of life and safety of SC AZA and oral decitabine/cedazuridine will also be reported.</p></div><div><h3>Conclusions</h3><p>This study aims to address an evidence gap in the comparison of patients’, carers’ and clinician's preference between an oral and a parenteral treatment, preference strength, and the reasons for it.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100440"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221304892400030X/pdfft?md5=d9b2f58e86f8ddbc12e6bbe36dc94e87&pid=1-s2.0-S221304892400030X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5-AZACITIDINE IN HIGH RISK MYELODYSPLASTIC SYNDROME-SINGLE CENTER EXPERIENCE","authors":"I. Mandac Smoljanovic,&nbsp;M. Grzelja","doi":"10.1016/j.lrr.2024.100442","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100442","url":null,"abstract":"<div><h3>Introduction</h3><p>Myelodysplastic syndrome (MDS) represents a group of malignant clonal hematological disorders characterized by dysplasia in one or more hematopoietic lineages in the bone marrow, leading to cytopenias and an increased risk of developing acute myeloid leukemia. The only treatment option that has shown benefit in PFS and OS for high-risk MDS is 5-azacitidine (5-AZA).</p></div><div><h3>Methods</h3><p>The aim of this study was to determine the impact of 5-AZA on the treatment outcome of patients with high-risk MDS from January 1, 2013, to December 31, 2021, at the Clinical Hospital Merkur in Zagreb, Croatia. Retrospective analysis was performed on data from patients with high-risk MDS. The study included 38 patients (M:F=25:13), at time of study conclusion, 34 patients died. Laboratory data and overall survival of the patients were analyzed. Data were analyzed using the Kaplan-Meier method, Log-rank test, and Mann-Whitney U test.</p></div><div><h3>Results</h3><p>A longer overall survival was observed in patients treated with more than 12 cycles of 5-AZA. The median survival of the group receiving more than 12 cycles of 5-AZA was 24 months, while the median survival of patients receiving less than 12 cycles was 11 months (p=0.023). Higher creatinine levels at diagnosis and lower LDH levels before the first cycle were observed in the group of surviving patients.</p></div><div><h3>Conclusions</h3><p>The results of this study highlight the efficacy of 5-AZA in the first-line treatment of high-risk MDS patients, with a statistically significant difference in overall survival observed in group of HR MDS patients receiving at least 12 cycles of 5-AZA.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100442"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000323/pdfft?md5=dd7b44a00b9e87af9c4f5d608a9d6f8e&pid=1-s2.0-S2213048924000323-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Posterior reversible encephalopathy syndrome (PRES) and myeloma","authors":"Ricardos Ghanem ,&nbsp;Sylvie Glaisner ,&nbsp;Arthur Bobin ,&nbsp;Anne-Marie Ronchetti ,&nbsp;Sophie Cereja ,&nbsp;Bertrand Joly ,&nbsp;Célia Salanoubat ,&nbsp;Guillemette Fouquet","doi":"10.1016/j.lrr.2023.100407","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100407","url":null,"abstract":"<div><p>Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated: hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment. Although rare, we must remain vigilant about PRES in myeloma patients. Stricter control of blood pressure could limit its occurrence.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100407"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221304892300047X/pdfft?md5=79ce5915187d635342b88c18f8a34c3e&pid=1-s2.0-S221304892300047X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139100131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic heterogeneity within B/T mixed phenotype acute leukemia in a context of an immunophenotype","authors":"Ruifang Zheng ,&nbsp;Franklin Fuda ,&nbsp;Jeffrey R. Gagan ,&nbsp;Olga K. Weinberg ,&nbsp;Prasad Koduru ,&nbsp;Miguel Cantu ,&nbsp;Kathleen Ludwig ,&nbsp;Jamie M. Truscott ,&nbsp;Robert Collins ,&nbsp;Stephen Chung ,&nbsp;Yazan F. Madanat ,&nbsp;Weina Chen","doi":"10.1016/j.lrr.2023.100410","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100410","url":null,"abstract":"<div><p>B/T mixed phenotype acute leukemia (MPAL) is a rare aggressive leukemia. Three cases of B/T MPAL were identified with comprehensive immunophenotypic, cytogenetic, and molecular studies. T-lineage predominant B/T MPAL shares a genetic signature with T-ALL whereas B/T lineage co-dominant B/T MPAL lacks such a T-ALL signature<em>.</em> All three patients were treated with lineage-matched-ALL therapy and alive at the last follow-up. Our study is the first to demonstrate molecular heterogeneity within B/T MPAL in a context of an immunophenotype of T-lineage versus B-lineage predominance. The implication of such a phenotype-genotype association on diagnostic classification is briefly discussed.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100410"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221304892300050X/pdfft?md5=dc5984f2e902dbb90e8b9e1ad03a0cf8&pid=1-s2.0-S221304892300050X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139108502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of AML using non-intensive chemotherapy in Jehovah's Witness patients","authors":"David Page,&nbsp;Daniel Sawler,&nbsp;Joseph Brandwein","doi":"10.1016/j.lrr.2024.100477","DOIUrl":"10.1016/j.lrr.2024.100477","url":null,"abstract":"<div><p>Acute myeloid leukemia (AML) patients undergoing induction chemotherapy receive transfusion support to manage severe cytopenias and associated sequelae. Jehovah's Witness (JW) patients typically decline transfusion of most or all blood products. This can lead to exclusion of JW patients from otherwise life-saving treatments due to safety concerns. We present two cases demonstrating the successful induction of JW patients without the need for red cell or platelet transfusion support; the first, an older AML patient induced with azacitidine &amp; venetoclax; the second, a patient with acute promyelocytic leukemia induced using arsenic trioxide and all-trans retinoic acid. Both patients required modifications to the induction regimens to accommodate their wishes. These cases support growing evidence that selected JW patients with AML can be successfully treated using appropriate accommodations.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"22 ","pages":"Article 100477"},"PeriodicalIF":0.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000670/pdfft?md5=a4e1f10b090b2b1a38c29e7419937478&pid=1-s2.0-S2213048924000670-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141985311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report","authors":"E. Amabile,&nbsp;F. Fazio,&nbsp;M. Martelli,&nbsp;MT. Petrucci","doi":"10.1016/j.lrr.2024.100491","DOIUrl":"10.1016/j.lrr.2024.100491","url":null,"abstract":"<div><div>POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M–protein, skin changes syndrome) is a rare condition due to an underlying plasma cell neoplasm whose clinical presentation can be various so it could lead to delayed diagnosis and treatment. The pathogenesis of the syndrome is not well understood, and its therapy is adapted from other plasma cell disorders with the aim of alleviating symptoms, decreasing end-organ damage, improving quality of life and prolonging overall survival. We report a case of a 71 years-old woman who has been treated with continuous DRd (daratumumab, lenalidomide and dexamethasone) scheme.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"22 ","pages":"Article 100491"},"PeriodicalIF":0.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}